Letters to the Editor

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia

State Key Laboratory of Experimental Hematolog; National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
State Key Laboratory of Experimental Hematolog
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
State Key Laboratory of Experimental Hematolog; National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
State Key Laboratory of Experimental Hematolog; National Clinical Research Center for Blood Disease; Leukemia center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Vol. 106 No. 5 (2021): May, 2021 https://doi.org/10.3324/haematol.2020.267526